Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customised Interleukin Therapies
ARScience Biotherapeutics, Inc., a clinical-stage biotechnology company specialising in the development and manufacturing of customised interleukins for in vivo use, today announced the appointment of Dr. Gustavo Mahler as Chief Executive Officer, effective July 1, 2026. Dr. Mahler transitions from his role as a member of the Company’s Board of Directors, where he has contributed strategic guidance as Arscience advances its mission to expand the boundaries of immunotherapy.
Dr. Mahler brings to Arscience over two decades of leadership across cell therapy, biopharmaceutical product development, and global general management. Most recently, he served as Chief Executive Officer of Cellistic and Ncardia, where he spearheaded both organisations’ strategic growth in the induced pluripotent stem cell (iPSC) space, focused on cell therapy product development and scaling cell therapy manufacturing capabilities. Prior to his work in the iPSC space, Dr. Mahler served as a Venture Partner at Dynamk Capital, investing in leading life sciences tools, technologies, and services. Before that, he spent a decade leading and growing AGC Biologics into a premier global contract development and manufacturing organisation and held senior global leadership positions at Bayer Healthcare.
“I am truly excited to step into the CEO role at ARScience Biotherapeutics at such a pivotal moment. I look forward to accelerating our programs and forging the partnerships that will bring these customised cytokine solutions to the patients who need them,” said Gustavo Mahler.
Claudia Zylberberg, Chair and Co-founder of ARScience Biotherapeutics, commented: “Gustavo’s appointment as CEO is a significant milestone for ARScience. His rare combination of deep scientific knowledge, particularly in cell therapy and biotherapeutic development space, with proven commercial and operational leadership makes him the ideal executive to lead our company into its next chapter.”
About ARScience Biotherapeutics
ARScience Biotherapeutics is a clinical-stage biotechnology company headquartered in Boca Raton, Florida, that specialises in developing and manufacturing customised interleukins for in vivo use. The Company’s mission is to expand the boundaries of immunotherapy through tailored cytokine solutions, driven by a passion to better serve the needs of patients. ARScience offers customised formulations and doses of its industry-leading interleukins to meet each patient’s unique therapeutic needs, recognising that impactful therapies must be as individual as the patients they treat.
The Company’s product pipeline includes ARS02, a subcutaneous low-dose IL-2 programme in IND for neurodegenerative conditions; ARS02C, a Treg-based combination therapy across multiple therapeutic areas; ARS15, an IL-15 program at First-in-Human stage for solid tumours; and ARS10, an IL-15 fusion protein in preclinical development for cancer. ARScience brings over 30 years of cytokine expertise, cGMP manufacturing capabilities, and more than 60,000 doses of commercial/clinical-grade IL-2 injected in patients, backed by strong partnerships with leading academic institutions and clinical groups.
For more information, visit www.arsciencebio.com or contact info@arsciencebio.com.
